Abstract Library

#4304 Co-targeting the Endocannabinoid System (ES) and mTOR in NEN potentiates their anti-tumour effect via unique metabolic changes

Introduction: The current treatment of neuroendocrine neoplasms (NEN) has limited efficacy, highlighting the need for novel therapeutic approaches. We have previously shown the potential therapeutic benefit when combining ES blocking with Everolimus (Eve).

Conference:

Presenting Author: Avniel-Polak S

Authors: Avniel-Polak S, Kogot-Levin A, Abramovich I, Agranovich B, Polak D,

Keywords: Neuroendocrine neoplasm, Endocannabinoid system, Everolimus, metabolic Changes, metabolomics,

#3961 Enhancer heterogeneity of lung carcinoids reveals sensitivity to FGF signaling inhibition

Introduction: Well-differentiated low grade lung carcinoids are histo-pathologically classified as typical and atypical, but each subtype is still heterogenous both at the molecular level and its clinical manifestation. Therefore, the treatment of these patients is challenging. The two main challenges are the lack of effective drug treatments and the lack of reliable biomarkers to guide management since the disease in patients with the same tumor grade/stage often has different clinical courses. The genetic, epigenetic, and developmental programs that drive lung carcinoids remain obscure, limiting our abilities to suggest new biomarkers and drug targets.

Conference:

Presenting Author: Drier Y

Authors: Davis E, Avniel-Polak S, Hecht M, Grozinsky-Glasberg S, Drier Y,

Keywords: FGF Signaling, Lung carcinoids, Enhancers,

#3664 Cannabis and endocannabinoid system modulation as novel strategies to improve conventional treatment outcomes and overcome drug resistance in neuroendocrine neoplasms in-vitro & in-vivo models

Introduction: NENs are treated with systemic therapies with limited non-curable efficacy due to development of drug resistance (DR). While cannabis and its extracts (cannabinoids, CE) are mostly used for their palliation properties, increasing evidence suggests an anticancer trait via several cellular pathways. Limited data exist on cannabis and the endocannabinoid system (ECS) in NENs and their impact on the development of DR.

Conference:

Presenting Author: Avniel-Polak S

Authors: Avniel- Polak S, Polak D, Drier Y, Grozinsky-Glasberg S,

Keywords: neuroendocrine neoplasm, cannabinoids, cannabis extracts, endocannabinoid system, endocannabinoid receptors, everolimus,

#3411 Cannabinoids and the Endocannabinoid System as modulatory targets in neuroendocrine neoplasms (NENs) – Possible mechanisms and antitumor efficacy

Introduction: Patients with unresectable NENs are offered a variety of non-curable therapeutic options, which eventually fail due to drug resistance (DR). Increasing evidence suggest an anticancer trait of cannabinoids, via cellular pathways including mTOR, known to be associated with DR development. Still, limited data exist on the anti-cancer effects of cannabinoids in NENs.

Conference:

Presenting Author: Avniel-Polak S

Authors: Avniel-Polak S, Polak D, Oleinikov K, Gross D, Wald O,

Keywords: neuroendocrine neoplasm, cannabinoids, endocannabinoid system, cannabis extracts, everolimus,

#1637 The Effect of the Autophagy Inhibitor Chloroquine (CQ), Alone or in Combination with mTOR Inhibitors, on Neuroendocrine Tumor (NET) Growth and Metastatic Spread in Mouse Models

Introduction: mTOR inhibitors (mTORi) such as RAD001 demonstrated promising anti-cancer effect in NETs. Autophagy, a cell survival mechanism, is activated by mTORi. We have recently shown in the human NET cell line BON1 that autophagy is essential for cell survival. Treatment with CQ alone or together with mTORi robustly inhibited cell proliferation and survival, suggesting that treatment with CQ may potentiate the anti-tumorigenic effects of mTORi.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Avniel-Polak S

Authors: Avniel-Polak S, Leibowitz G, Gross D, Grozinsky-Glasberg S,

Keywords: autophagy, mTORi, NET,